nivolumab + ramucirumab + docetaxel

This is a combination regimen consisting of **nivolumab**, **ramucirumab**, and **docetaxel**, used primarily in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first-line therapies. **Nivolumab** is an immune checkpoint inhibitor, specifically a monoclonal antibody against the programmed cell death protein 1 (PD-1), which enhances the immune system's response to cancer by blocking PD-1-mediated inhibition of T cells. **Ramucirumab** is a fully human monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting angiogenesis—preventing the formation of new blood vessels needed for tumor growth. **Docetaxel** is a cytotoxic taxane chemotherapy agent that disrupts microtubule function, leading to cell cycle arrest and apoptosis in rapidly dividing cells. Together, this combination targets cancer through immune modulation, anti-angiogenesis, and direct cytotoxic effects. There is clinical evidence supporting improved outcomes when ramucirumab plus docetaxel are used after progression on nivolumab in NSCLC patients[1][3][5].